Shots:
- AbbVie has reported topline P-III (UP-AA) trial data on Rinvoq (QD) for sev. alopecia areata in pts with a mean baseline SALT score of 84
- Trial incl. 2 replicate studies (Study 1 & 2) in AA pts (n=1399; 12-64yrs.), where in both studies’ Period A, pts were randomized to Rinvoq 15mg, 30mg, or PBO for 24wks. & in Period B, treatment continued or changed for 28wks. based on SALT score at wk. 24; Study 2 data was previously reported
- In Study 1, Rinvoq met the 1EP, with 45.2% & 55% vs 1.5% pts reaching ≥80% scalp hair coverage (SALT ≤20); 35.2% & 45.8% reached ≥90% coverage (SALT ≤10) vs 0.7%, with significant improvements also seen in eyebrows, eyelashes, & complete scalp hair coverage SALT=0 (2EPs) at 24wks.
Ref: AbbVie | Image: AbbVie | Press Release
Related News:- AbbVie Reports the US FDA’s sNDA Submission of Venclexta + Acalabrutinib for Chronic Lymphocytic Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
